CatalystMarker
← board

RVRC

distress 6/10 · elevated risk
$1.670%today0% from 52w high
reviumrx.com3 employeesFounded 1997Herzliya, IsraelHealth Information Services
Revenue
pre-revenue
Liquidity
$1M
Runway
0.4 yrs
Shares 1y
-1%

Price & events

+11.3% over 6M
$1.50$1.58$1.67Jan 26Apr 26Jul 26101dilution: EFFECT shelf_effective (2026-01-30)dilution: S-1/A shelf_registration (2026-01-28)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
+11.3%
6M
+234.0%
1Y
+11.3%
2Y
+32.5%
5Y
+40.3%
All

Overview

Market Cap
$101.42M
Volume
0
52 Week Range
$0.50 – $1.67
Total Shares
60.73M
Float Shares
21.92M
% Held by Insiders
56.70%
% Held by Institutions
0.00%
Beta
-0.78

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 60,729,100 · 0 offerings/1y · 0 PIPEs
  • 2026-01-30EFFECTshelf_effective
  • 2026-01-28S-1/Ashelf_registration
  • 2026-01-16S-1/Ashelf_registration
  • 2025-12-12S-1/Ashelf_registration
  • 2025-10-03S-1/Ashelf_registration
  • 2025-08-13S-1/Ashelf_registration
  • 2025-02-14S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.